Preclinical Studies with Human Tumour Xenografts Using Rat Monoclonal Antibodies Directed Against the Epidermal Growth Factor Receptor
There is abundant evidence to suggest that over-expression of growth factor receptors and/or autocrine production of one or more ligands may provide tumour cells with significant advantages in growth and dissemination. One clinically important group is that of the c-erbB family of type 1 receptor tyrosine kinases exemplified by epidermal growth factor receptor (EGFR; reviewed by Harris et al. 1992; Khazaie et al. 1993; Modjtahedi and Dean 1994; Baselga and Mendelsohn 1994; Eccles et al. 1995). The cell surface location of these molecules renders them attractive targets for a variety of immunotherapeutic strategies, some of which are showing promise in preclinical and early clinical trials.
KeywordsToxicity Carbohydrate Tyrosine Adenocarcinoma Oncol
Unable to display preview. Download preview PDF.
- Eccles S, Modjtahedi H, Box G, Court W, Sandle J, Dean C (1995) Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis 14:337–348Google Scholar
- Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4:227–296Google Scholar
- Modjtahedi H, Styles J, Box G, Eccles S, Gusterson B, Dean C (1993b) Antitumour activity of rat Mabs to the human receptor for EGF. In: Epenetos AA, Lemoine NR (eds) Mutant oncogenes: targets for therapy? Chapman and Hall, London, p 35Google Scholar
- Modjtahedi H, Jackson E, Dean C (1995) Monovalent antibodies to the epidermal growth factor (EGF) receptor: effects on proliferation and differentiation of tumors overexpressing the EGF receptor. Tumor Target 1:99–106Google Scholar
- Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M (1996) Phase 1 trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 73:228–235PubMedCrossRefGoogle Scholar